Who is eligible for clinical trial NCT05268887?

Participants must meet protocol criteria for Parkinson Disease. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05268887 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-30

High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease (NCT05268887)

🟢 Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Massachusetts Institute of Technology

🩺 Plain-English Summary (8th-Grade Level)

Parkinson's disease (PD) impacts different types of neural oscillations in the brain, including beta (13-30Hz) and gamma oscillations (30-80Hz), which contributes to PD's cardinal symptoms of resting tremor, rigidity, bradykinesia (slowness of movement), and gait instability. The investigators' lab has developed a non-invasive method of increasing gamma power in the brain using Gamma Entrainment Using Sensory Stimulation (GENUS) through light, sound, and tactile stimulation devices. For this study, 40 participants with mild Parkinson's disease will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) before, during, and after light, sound, and tactile stimulation to determine the safety, feasibility, and optimization of GENUS as a potential therapy in the PD population.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (16 items).

Location: Massachusetts Institute of Technology — Cambridge, Massachusetts

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Subject has Idiopathic PD defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor or rigidity and without any other known or suspected cause of Parkinsonism (according to Movement disorder society (MDS) clinical diagnostic criteria for Parkinson's disease confirmed by a fellowship trained movements disorder specialist
Subject is Hoehn \& Yahr stage 2 to 3
Subject has a Montreal Cognitive Assessment (MOCA) score ≥26.
Subject is \> 45 and \<90 years of age.
proficient in speaking, reading, and understanding English
capable of providing informed written consent
Subject is on a stable dose (at least 1 month prior to baseline visit) of antiparkinsonian agents and willing to remain on this dose for the duration of the study. If on a cholinesterase inhibitor, a stable dose without changes for 1 month is required.
Subject has undergone a brain CT or MRI prior to rule out underlying structural lesions

Usually NOT eligible if any of the following apply:

Exclusion criteria:
Subject has atypical Parkinson's syndrome(s) due to drugs, metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Lewy Body dementia)
history of any psychiatric illness that would pose a safety risk
diagnosis of dementia or other neurological conditions
currently taking sedative medications that are clinically contraindicated
has undergone recent change (\<1 month) in medication
recent drug or alcohol abuse or dependence
laboratory results the would pose safety risk
concurrently or has participated in other clinical trial investigation within 3 months
pregnant
no healthcare
history of epilepsy, stroke, or seizure in past 24 months

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Massachusetts Institute of Technology — Cambridge, Massachusetts

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗